Cover Image
市場調查報告書

Cavion LLC的產品平台分析

Cavion LLC - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 321995
出版日期 內容資訊 英文 24 Pages
訂單完成後即時交付
價格
Back to Top
Cavion LLC的產品平台分析 Cavion LLC - Product Pipeline Review - 2014
出版日期: 2014年12月24日 內容資訊: 英文 24 Pages
簡介

Cavion LLC是總公司設立於美國的製藥企業,從事固態腫瘤治療藥等的開發。現在臨床開發中的mibefradil dihydrochloride是T型鈣離子阻斷劑,為高血壓的治療藥。該公司同時也與各個大學和研究機關一起進行前臨床研究。

本報告提供Cavion LLC 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Cavion LLC 基本資料

  • Cavion LLC 概要
  • 主要資訊
  • 企業資料

Cavion LLC :R&D概要

  • 主要的治療範圍

Cavion LLC :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Cavion LLC :開發中產品概況

  • 臨床階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Cavion LLC :藥物簡介

  • mibefradil dihydrochloride
  • Small Molecules to Block Cav3.2 for Neuropathic pain
  • TTL-1177

Cavion LLC :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Cavion LLC :最新的開發平台資訊

Cavion LLC :開發暫停中的計劃

Cavion LLC :總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

目錄
Product Code: GMDHC06750CDB

Summary

Global Markets Direct's, 'Cavion LLC - Product Pipeline Review - 2014', provides an overview of the Cavion LLC's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Cavion LLC's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Cavion LLC including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Cavion LLC's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Cavion LLC's pipeline products

Reasons to buy

  • Evaluate Cavion LLC's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Cavion LLC in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Cavion LLC's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Cavion LLC and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Cavion LLC
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Cavion LLC and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Cavion LLC Snapshot
    • Cavion LLC Overview
    • Key Information
    • Key Facts
  • Cavion LLC - Research and Development Overview
    • Key Therapeutic Areas
  • Cavion LLC - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Cavion LLC - Pipeline Products Glance
    • Cavion LLC - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Cavion LLC - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Cavion LLC - Drug Profiles
    • mibefradil dihydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Block Cav3.2 for Neuropathic pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TTL-1177
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Cavion LLC - Pipeline Analysis
    • Cavion LLC - Pipeline Products by Target
    • Cavion LLC - Pipeline Products by Route of Administration
    • Cavion LLC - Pipeline Products by Molecule Type
    • Cavion LLC - Pipeline Products by Mechanism of Action
  • Cavion LLC - Recent Pipeline Updates
  • Cavion LLC - Dormant Projects
  • Cavion LLC - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Cavion LLC, Key Information
  • Cavion LLC, Key Facts
  • Cavion LLC - Pipeline by Indication, 2014
  • Cavion LLC - Pipeline by Stage of Development, 2014
  • Cavion LLC - Monotherapy Products in Pipeline, 2014
  • Cavion LLC - Phase I, 2014
  • Cavion LLC - Preclinical, 2014
  • Cavion LLC - Pipeline by Target, 2014
  • Cavion LLC - Pipeline by Route of Administration, 2014
  • Cavion LLC - Pipeline by Molecule Type, 2014
  • Cavion LLC - Pipeline Products by Mechanism of Action, 2014
  • Cavion LLC - Recent Pipeline Updates, 2014
  • Cavion LLC - Dormant Developmental Projects,2014

List of Figures

  • Cavion LLC - Pipeline by Top 10 Indication, 2014
  • Cavion LLC - Pipeline by Stage of Development, 2014
  • Cavion LLC - Monotherapy Products in Pipeline, 2014
  • Cavion LLC - Pipeline by Top 10 Target, 2014
  • Cavion LLC - Pipeline by Top 10 Route of Administration, 2014
  • Cavion LLC - Pipeline by Top 10 Molecule Type, 2014
  • Cavion LLC - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top